News
-
Jan 26, 2021- Galmed KOL Symposium and Pipeline Update taking place later today at 11 a.m. Eastern time
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced upcoming...
-
Jan 19, 2021Aramchol Phase 3 Trial for Non-Alcoholic Steatohepatitis and Liver Fibrosis
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, announced today that it will host...
Dec 17, 2020New Phase 1 Data Confirm Aramchol Meglumine PK Parameters Similar to Aramchol AcidGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the addition of an...
- Nov 12, 2020- Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT -
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an...
Nov 9, 2020Collaboration Seeks to Enhance Response Rate and Identify Biomarker for Treatment of NASH and FibrosisGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) and MyBiotics Pharma Ltd. announced today they have entered into a research and development collaboration agreement to identify and optimize the selected...
